top of page

Our latest thinking, insights and company news

CONTACT US TODAY

Request more information about RJW&partners

RJW&partners will only use your personal information to administer your account and provide the products and services you request. You can unsubscribe at any time, to do so please review our Privacy Policy. By clicking subscribe, you consent to allow RJW&partners to store and process your personal information.

Early Access Programmes in Europe Versus Key Markets in Other Regions: An In-Depth Comparison

Early Access Programmes in Europe Versus Key Markets in Other Regions: An In-Depth Comparison

Early Access Programmes in Europe Versus Key Markets in Other Regions: An In-Depth Comparison

Early Access Programmes in Europe Versus Key Markets in Other Regions: An In-Depth Comparison

Dec 10, 20244 min read

Can we afford future cell and gene therapies? Payer perspectives on sustainable reimbursement

Can we afford future cell and gene therapies? Payer perspectives on sustainable reimbursement

Can we afford future cell and gene therapies? Payer perspectives on sustainable reimbursement

Cell and gene therapies (CGTs) offer lifelong benefits to patients, but can payers afford them as more therapies come to the market?

Mar 11, 202413 min read

The Rise of Brazil and Expanded Access Programs: A strategic opportunity?

The Rise of Brazil and Expanded Access Programs: A strategic opportunity?

The Rise of Brazil and Expanded Access Programs: A strategic opportunity?

Brazil has a large and growing population, a rising middle-class, an aging society, and a commitment to increased investment in healthcare.

Nov 13, 20239 min read

Risk-Sharing Agreements: a fancy way to discount?

Risk-Sharing Agreements: a fancy way to discount?

Risk-Sharing Agreements: a fancy way to discount?

Risk-Sharing Agreements have been hailed as a solution to attain access for innovative medicines with limited evidence packages or high...

Aug 11, 20239 min read

One step forward, two steps back: Is the UK driving away pharmaceutical manufacturers?

One step forward, two steps back: Is the UK driving away pharmaceutical manufacturers?

One step forward, two steps back: Is the UK driving away pharmaceutical manufacturers?

The UK voluntary scheme payback rate on NHS sales of branded medicines was set to 26.5%. Is the UK driving away pharmaceutical companies?

Jun 14, 20237 min read

Why early consideration of Market Access means a better night’s sleep

Why early consideration of Market Access means a better night’s sleep

Why early consideration of Market Access means a better night’s sleep

Why early P&MA planning is always a good investment

Mar 21, 20238 min read

bottom of page